8 withdrawn. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Withdrawn 8 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Nose Diseases: new trials by email Literature Review of Nose Diseases trials Research Report on Nose Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Withdrawn | Terremoto Biosciences Inc. | 2025-12-15 | 2026-04-13 | |
| Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers HA115, Placebo - Asthma | Phase 1 | Withdrawn | Conjupro Biotherapeutics, Inc. | 2021-10-01 | 2021-09-08 | |
| Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol - Allergic Rhinitis | Phase 1 / Phase 2 | Withdrawn | Bryan Martin, DO | 2013-03-01 | 2021-10-28 | |
| Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Ranibizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | Phase 1 | Withdrawn | University of California, San Diego | 2011-07-01 | 2013-04-29 | |
| Study of AHIST in Seasonal Allergic Rhinitis Patients AHIST NDC#58407-012-01 - Rhinitis, Allergic, Seasonal | Phase 1 | Withdrawn | Magna Pharmaceuticals, Inc. | 2011-04-01 | 2014-03-06 | |
| Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract dust mite inhalation - Dermatophagoides Farinae Allergy, Asthma | Phase 1 | Withdrawn | University of North Carolina, Chapel Hill | 2009-01-01 | 2017-05-05 | |
| Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma QAX576, Placebo - Asthma | Phase 1 / Phase 2 | Withdrawn | Novartis | 2008-01-01 | 2016-03-04 |
Asthma (4) · Rhinitis, Allergic (4) · Epistaxis (2) · Telangiectasia, Hereditary Hemorrhagic (2) · Anemia (1) · Arteriovenous Malformations (1) · Dermatitis, Atopic (1) · Dust Mite Allergy (1) · Egg Hypersensitivity (1) · Food Hypersensitivity (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Milk Hypersensitivity (1) · Nut Hypersensitivity (1) · Peanut Hypersensitivity (1)
Otorhinolaryngologic Diseases (8) · Respiratory Tract Diseases (8) · Immune System Diseases (6) · Respiratory Hypersensitivity (6) · Hypersensitivity (5) · Hypersensitivity, Immediate (5) · Rhinitis (5) · Bronchial Diseases (4) · Lung Diseases (4) · Lung Diseases, Obstructive (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Congenital Abnormalities (2)
Allergens (1) · Anti-Allergic Agents (1) · Dust (1) · Ranibizumab (1) · Sensitivity and Specificity (1) · Sodium Chloride (1)
Bryan Martin, DO (1) · Candid Therapeutics (1) · Conjupro Biotherapeutics, Inc. (1) · Magna Pharmaceuticals, Inc. (1) · Novartis (1) · Terremoto Biosciences Inc. (1) · University of California, San Diego (1) · University of North Carolina, Chapel Hill (1)
United States (4) · Australia (1)
Bryan Martin, DO (1) · David Peden, MD (1) · Michelle Hernandez, MD (1) · Stephen J Pollard, MD (1) · Terence Davidson, M.D. (1)